Enanta Pharmaceuticals has announced the filing of a patent infringement suit against Pfizer in the Unified Patent Court of the European Union. The suit concerns the alleged infringement of European Patent No. EP 4 051 265, which involves coronavirus protease inhibitors. Enanta is seeking a determination of liability related to the manufacture, use, and sale of Pfizer's COVID-19 antiviral, Paxlovid. The patent is the European counterpart of a U.S. patent involved in ongoing litigation between the two companies. A hearing in the UPC is expected to take place within 12 months, with a decision to follow shortly thereafter.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。